These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 8485531)

  • 1. Statistical methods for a three-period crossover design in which high dose cannot be used first.
    Peace KE; Koch GG
    J Biopharm Stat; 1993 Mar; 3(1):103-16. PubMed ID: 8485531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mixed-model analysis of incomplete longitudinal data from a high-dose trial of tacrine (Cognex) in Alzheimer's patients.
    Smith F
    J Biopharm Stat; 1996 Mar; 6(1):59-67. PubMed ID: 8838779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.
    Davis KL; Thal LJ; Gamzu ER; Davis CS; Woolson RF; Gracon SI; Drachman DA; Schneider LS; Whitehouse PJ; Hoover TM
    N Engl J Med; 1992 Oct; 327(18):1253-9. PubMed ID: 1406817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intent-to-treat analysis for longitudinal studies with drop-outs.
    Little R; Yau L
    Biometrics; 1996 Dec; 52(4):1324-33. PubMed ID: 8962456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. Results of a Canadian double-blind, crossover, multicenter study.
    Gauthier S; Bouchard R; Lamontagne A; Bailey P; Bergman H; Ratner J; Tesfaye Y; Saint-Martin M; Bacher Y; Carrier L
    N Engl J Med; 1990 May; 322(18):1272-6. PubMed ID: 2183056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of the randomized controlled trials of tacrine in the treatment of Alzheimer's disease: methodologic considerations.
    Conway EL
    Clin Neuropharmacol; 1998; 21(1):8-17. PubMed ID: 9579280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis of continuous outcome data from individual patients.
    Higgins JP; Whitehead A; Turner RM; Omar RZ; Thompson SG
    Stat Med; 2001 Aug; 20(15):2219-41. PubMed ID: 11468761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using the partitioning principle to adaptively design dose-response studies.
    Ling X; Hsu J
    J Biopharm Stat; 2006; 16(5):733-43. PubMed ID: 17037268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of repeated measurements with dropouts among Alzheimer's disease patients using summary measures and meta-analysis.
    Talwalker S
    J Biopharm Stat; 1996 Mar; 6(1):49-58. PubMed ID: 8838778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statistical methods for active extension trials.
    Hu Z; Follmann D
    Stat Med; 2007 May; 26(12):2433-48. PubMed ID: 17066400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of survival analysis techniques in evaluating the effect of long-term tacrine (Cognex) treatment on nursing home placement and mortality in patients with Alzheimer's disease.
    Smith F; Talwalker S; Gracon S; Srirama M
    J Biopharm Stat; 1996 Nov; 6(4):395-409. PubMed ID: 8969976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multivariate nonparametric analysis for the two-period crossover design with application in clinical trials.
    Johnson WD; Grender JM
    J Biopharm Stat; 1993 Mar; 3(1):1-12. PubMed ID: 8485530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caregiver time use: an outcome measure in clinical trial research on Alzheimer's disease.
    Clipp EC; Moore MJ
    Clin Pharmacol Ther; 1995 Aug; 58(2):228-36. PubMed ID: 7648773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How to deal with multiple treatment or dose groups in randomized clinical trials?
    Hothorn LA
    Fundam Clin Pharmacol; 2007 Apr; 21(2):137-54. PubMed ID: 17391286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: results of a randomized, double-blind, parallel-group multicenter study.
    Gutzmann H; Kühl KP; Hadler D; Rapp MA
    Pharmacopsychiatry; 2002 Jan; 35(1):12-8. PubMed ID: 11819153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring and reporting of the Women's Health Initiative randomized hormone therapy trials.
    Anderson GL; Kooperberg C; Geller N; Rossouw JE; Pettinger M; Prentice RL
    Clin Trials; 2007; 4(3):207-17. PubMed ID: 17715246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parametric versus non-parametric statistics in the analysis of randomized trials with non-normally distributed data.
    Vickers AJ
    BMC Med Res Methodol; 2005 Nov; 5():35. PubMed ID: 16269081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crossover trials with a cumulative response.
    Walter SD
    J Biopharm Stat; 1997 Nov; 7(4):649-66. PubMed ID: 9358336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fallback tests in dose-response clinical trials.
    Dmitrienko A; Wiens B; Westfall P
    J Biopharm Stat; 2006; 16(5):745-55. PubMed ID: 17037269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Should Alzheimer disease be treated with tacrine? Review of the literature].
    Arsland D; Laake K
    Tidsskr Nor Laegeforen; 1996 Sep; 116(23):2791-4. PubMed ID: 8928167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.